Why Grade III/IV knee OA rarely responds to a single injection

Advanced knee osteoarthritis is not a single-tissue problem. By Kellgren-Lawrence Grade III or IV, meaningful damage has typically accumulated at two anatomically separate sites: the articular cartilage covering the load-bearing bone ends, and the synovial membrane lining the joint capsule. Each compartment drives symptoms through its own mechanism — cartilage loss removes the joint's structural buffer, while synovial dysfunction sustains inflammation, fluid excess, and pain signalling that no amount of cartilage treatment alone can fully address.

This is precisely where single-injection protocols tend to fall short. Treat the cartilage surface and leave the synovium untouched, and synovial inflammation continues to accelerate joint deterioration. Address the synovium only, and the eroded cartilage remains exposed. In either scenario, relief is incomplete and typically short-lived in proportion to what was left untreated.

The ChondroFiller and Arthrosamid Dual Active Therapy is designed around that dual pathology. ChondroFiller — an injectable collagen scaffold — targets the cartilage surface; Arthrosamid, a polyacrylamide hydrogel, integrates into the synovial lining. The two products work through mechanistically distinct pathways and act on different anatomical structures. Both are delivered in a single ultrasound-guided outpatient session, not a surgical procedure.

How ChondroFiller works at the cartilage surface

ChondroFiller liquid is a CE-marked Class III medical device — 2.3 mL of acellular, murine-derived Type I collagen — placed directly onto the load-bearing cartilage surfaces under ultrasound guidance during a single outpatient appointment. On contact with the joint environment, the collagen solution gels in situ, forming a three-dimensional scaffold that conforms to the worn surface.

The structural effect that follows is driven not by the collagen itself, but by what it recruits. The scaffold acts as a chemotactic signal, drawing the patient's own progenitor cells inward from the surrounding synovial tissue and subchondral bone. Those cells migrate into the matrix and begin depositing new cartilage material — a process known as acellular matrix-induced chondrogenesis, or, in plain terms: the scaffold provides a physical home for the patient's own cells to move into and start building cartilage matrix from the ground up. ChondroFiller supports the body's own repair processes rather than replacing the tissue with a synthetic substitute.

This is not a surface lubricant or a space-filler. The repair tissue matures progressively; published evidence describes the structural changes emerging over 6–12 months as the cellular activity consolidates into organised cartilage matrix.

In the context of the Dual Active Therapy, ChondroFiller is specifically the articular-surface component — the regenerative, bottom-up element targeting structural restoration at the bone ends. It does not act on the synovial membrane; that role belongs to Arthrosamid, covered in the next section.

Arthrosamid's role in the synovial lining

Where ChondroFiller works from the bone ends upward, Arthrosamid works from the synovial lining inward — and the distinction matters.

Arthrosamid is a hydrogel composed of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water. The 6 mL volume is injected into the synovial membrane under ultrasound guidance — a separate anatomical compartment entirely from the cartilage surface addressed by ChondroFiller. Once in place, the hydrogel adheres to the membrane and forms a durable mechanical cushion. Over time, a layer of the patient's own infiltrating synovial lining cells grows over it, incorporating it into the joint's soft-tissue architecture. The hydrogel is non-biodegradable and non-resorbable, meaning it does not break down or get absorbed; it remains in the joint on a permanent basis.

The effect is mechanical rather than regenerative. Arthrosamid reduces load transmission and synovial irritation; it does not recruit progenitor cells, does not lay down new cartilage matrix, and should not be described as a scaffold in the ChondroFiller sense. In the Dual Active Therapy, it is the top-down, symptom-modifying component — its role is to cushion and calm the joint environment while ChondroFiller addresses structural repair at the cartilage surface.

Published clinical evidence, including a 52-week prospective study by Bliddal et al., documents significant symptom improvement in knee osteoarthritis; relief from a single injection typically extends to 2–3 years.

What the clinical evidence shows for each product

The two components of the Dual Active Therapy each carry an independent evidence base — substantial for ChondroFiller, meaningful for Arthrosamid, but currently separate rather than joined in a single combined trial.

ChondroFiller: structural and functional outcomes

The strongest data come from the post-market clinical follow-up (PMCF) study by Jerosch et al., which tracked patients for three years. Mean IKDC score improvement reached 32.4 points and was sustained — and marginally increased — at the three-year mark, with the patient group reaching a mean functional score of 80. The minimum clinically important difference (MCID) for the IKDC is 16.7 points; the Jerosch et al. cohort exceeded that threshold by a considerable margin. Across multiple European studies, IKDC gains of approximately 30 points at one year appear consistent rather than exceptional to a single dataset.

MRI-based MOCART scoring in the same evidence base confirms the structural picture: scores ranged from 81.6 to 84.3 at three years, reflecting greater than 80% defect filling and integration of repair tissue into the surrounding native cartilage. Progression from a MOCART score of 65.3 at four weeks to 81.6 at one year follows the pattern expected of maturing repair tissue — not an immediate effect but a consolidating one.

Arthrosamid: symptom and tissue-level evidence

For Arthrosamid, the 52-week prospective study by Bliddal et al. demonstrated significant symptom improvements in knee osteoarthritis across the follow-up period. Separately, Maulana, Cole and Lee (2022) documented a reduction in patellofemoral bone marrow lesions following a single Arthrosamid injection — a finding relevant to patients with subchondral involvement alongside synovial dysfunction.

The combination as a protocol: honest assessment

No randomised controlled trial has evaluated the ChondroFiller plus Arthrosamid combination as a single entity. The evidence for the Dual Active Therapy as a paired protocol is currently clinician-described rather than trial-derived. That is worth stating plainly, not as a reason to dismiss the approach, but because patients making informed decisions deserve to know where the evidence sits. The mechanistic rationale — two products targeting two anatomically distinct structures — is coherent, and the component-level evidence for each is independently robust. What does not yet exist is a dedicated RCT assessing whether the combination produces outcomes that exceed either product used alone.

What to expect from the treatment session and recovery

Both injections are delivered in a single in-clinic appointment under ultrasound guidance. There is no theatre admission, no general anaesthetic, and no incisions — the entire session takes place on an outpatient basis, and patients leave the same day.

The two products then operate on quite different timescales, and understanding that distinction helps calibrate realistic expectations. Arthrosamid's cushioning effect is mechanical: the hydrogel is in place from the moment of injection, and many patients notice symptom relief developing over the early weeks as the joint environment settles. That relief is expected to extend to 2–3 years from a single injection. ChondroFiller, by contrast, works biologically — the collagen scaffold needs time for the patient's own cells to migrate in, mature, and begin depositing new cartilage matrix. Structural benefit builds gradually over 6–12 months, with MRI evidence of progressive repair tissue maturation continuing across that window.

For patients where additional biologic support is clinically appropriate, a Tri-Active option exists — adding autologous mesenchymal stem cells to the two-injection protocol, priced at £11,000.

Longer term, a Longitudinal Lifetime Programme offers ongoing joint preservation: yearly MRI monitoring, peptide therapy, and bi-annual ChondroFiller top-up injections to maintain repair tissue over time. Individual suitability for any of these options is assessed at consultation.

Cost, insurance, and who is a suitable candidate

The Dual Active Therapy carries a guide cost of £6,000 per joint — a figure that should be confirmed with the treating clinic at assessment, as individual clinical factors may affect final pricing. To understand what that represents, the standalone costs offer a useful reference: Arthrosamid is priced from £3,000 for a single box (all-inclusive of consultation, ultrasound, product, and six-week follow-up), and ChondroFiller ranges from £3,000 to £8,000 depending on quantity. On that basis, the combined protocol represents meaningful bundling relative to the sum of its parts.

Both the Dual Active Therapy and standalone Arthrosamid are self-funded private treatment. There is no NHS pathway, and private medical insurance does not currently cover the combined injection protocol. ChondroFiller procedures billed as surgical interventions carry CCSD codes W3111 and W8500, with approvals reported by Bupa, Aviva, and WPA — but those codes apply to the surgical delivery route, not the injection-only Dual Active pathway. Patients expecting to use insurance should confirm their policy position at assessment rather than assume those approvals extend to the in-clinic injection protocol.

Who is typically considered suitable

The therapy is designed for confirmed Kellgren-Lawrence Grade III or IV osteoarthritis — joints where both cartilage wear at the bone ends and synovial dysfunction are present, and where conservative measures have already been tried. Stable joint mechanics are a clinical prerequisite for both products. Because OA presentation varies considerably at this stage, individual assessment is the correct route to determine whether the Dual Active Therapy, a standalone component, or another pathway best matches a patient's anatomy and goals.

Patients can arrange that assessment through londoncartilage.com.